Micro RNAs to Predict Response to Androgen Deprivation Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

42 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-04-29

Study Completion Date

2021-05-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Identify exosomal micro RNA that predict responses to ADT

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

NCT00668642

Prostate Cancer

COMPLETED PHASE2

Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs

NCT04662996

Prostate Cancer Resistance, Disease MicroRNAs

ACTIVE_NOT_RECRUITING NA

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

NCT01023061

Adenocarcinoma of the Prostate Stage II Prostate Cancer Stage III Prostate Cancer +1 more

COMPLETED PHASE2

Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

NCT01344564

Prostate Cancer

COMPLETED NA

Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

NCT00536653

Osteoporosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Identify novel exosomal RNA signatures at pretreatment that predict response to ADT.

The study team will collect blood samples from patients with systemic disease pretreatment (at enrollment), three months post-treatment and at the time of progression of disease (or at two years post-ADT for patients still in remission at that time point) and then perform next-generation sequencing using serum exosomal RNAs derived from these patients.

The investigators plan to identify exosomal RNAs signatures that change between pretreatment (at enrollment) and during treatment (at three months) and further explore the effect of these changes on disease response. The investigators also plan to compare exosomal RNA levels between patients relapse within the first two years versus those in remission at two years. Among patients with progression, the investigators plan to compare exosomal RNA signatures at progression of disease to signatures at pretreatment and during treatment.
2. Validate exosomal RNA markers that predict response to ADT by real-time RT-PCR.

Secondary objectives: Selected RNAs, identified through the above process will be validated using real-time RT-PCR assay to test reproducibility of RNA sequencing results. The investigators expect to select and validate approximate five RNA markers that predict duration of response to ADT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Androgen blockade

Androgen DeprivationTherapy or Complete Androgen Blockade

Bicalutamide

Intervention Type DRUG

ANDROGEN BLOCKADE

Leuprolide

Intervention Type DRUG

ANDROGEN BLOCKADE

Goserelin

Intervention Type DRUG

ANDROGEN BLOCKADE

Triptorelin

Intervention Type DRUG

ANDROGEN BLOCKADE

Intervention Type DRUG

Nonsteroidal antiandrogen medication

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven prostate cancer.
* Testosterone level \>30ng/ml and at least 6 months since last dose of hormonal therapy.
* History/physical examination including a detailed description of the stage of prostate cancer within 8 weeks prior to registration.
* CT scan of abdomen and pelvis with IV contrast and bone scan should be performed within 8 weeks prior to registration.
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
* Age ≥ 18.
* Patients must provide study-specific informed consent prior to study entry for this project and mandatory blood specimen for banking for future studies (future studies may include genetic testing).

Exclusion Criteria

* Received hormonal therapy less than 6 months prior to registration.
* History of active secondary malignancy.
* Decline hormone therapy for prostate cancer.
* Current or previous treatment with 5-alpha reductase inhibitors within 6 months prior to enrollment.

Minimum Eligible Age

21 Years

Maximum Eligible Age

85 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No